Titre : Trouble lié au tabagisme

Trouble lié au tabagisme : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Trouble lié au tabagisme : Questions médicales les plus fréquentes", "headline": "Trouble lié au tabagisme : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Trouble lié au tabagisme : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-31", "dateModified": "2025-03-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Trouble lié au tabagisme" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Troubles liés à une substance", "url": "https://questionsmedicales.fr/mesh/D019966", "about": { "@type": "MedicalCondition", "name": "Troubles liés à une substance", "code": { "@type": "MedicalCode", "code": "D019966", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "F03.900" } } }, "about": { "@type": "MedicalCondition", "name": "Trouble lié au tabagisme", "alternateName": "Tobacco Use Disorder", "code": { "@type": "MedicalCode", "code": "D014029", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Joseph Guydish", "url": "https://questionsmedicales.fr/author/Joseph%20Guydish", "affiliation": { "@type": "Organization", "name": "Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: joseph.guydish@ucsf.edu." } }, { "@type": "Person", "name": "Thao Le", "url": "https://questionsmedicales.fr/author/Thao%20Le", "affiliation": { "@type": "Organization", "name": "Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: thao.le@ucsf.edu." } }, { "@type": "Person", "name": "Kevin Delucchi", "url": "https://questionsmedicales.fr/author/Kevin%20Delucchi", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave., San Francisco, CA 94143, United States of America. Electronic address: kevin.delucchi@ucsf.edu." } }, { "@type": "Person", "name": "Guang-Heng Dong", "url": "https://questionsmedicales.fr/author/Guang-Heng%20Dong", "affiliation": { "@type": "Organization", "name": "Department of Psychology, Yunnan Normal University, Kunming, Yunnan Province, PR China. Electronic address: dongguangheng@ynnu.edu.cn." } }, { "@type": "Person", "name": "Caravella McCuistian", "url": "https://questionsmedicales.fr/author/Caravella%20McCuistian", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry and Behavioral Sciences, University of California, San Francisco 1001 Potrero Ave, San Francisco, CA 94110, United States. Electronic address: caravella.mccuistian@ucsf.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36253300", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clgc.2022.09.007" } }, { "@type": "ScholarlyArticle", "name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.", "datePublished": "2024-10-20", "url": "https://questionsmedicales.fr/article/39428439", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-76355-4" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Troubles mentaux", "item": "https://questionsmedicales.fr/mesh/D001523" }, { "@type": "ListItem", "position": 3, "name": "Troubles liés à une substance", "item": "https://questionsmedicales.fr/mesh/D019966" }, { "@type": "ListItem", "position": 4, "name": "Trouble lié au tabagisme", "item": "https://questionsmedicales.fr/mesh/D014029" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Trouble lié au tabagisme - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Trouble lié au tabagisme", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Trouble lié au tabagisme", "description": "Comment diagnostiquer un trouble lié au tabagisme ?\nQuels critères sont utilisés pour le diagnostic ?\nQui peut poser le diagnostic ?\nY a-t-il des tests spécifiques pour le diagnostic ?\nLe diagnostic peut-il être fait à distance ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Trouble lié au tabagisme", "description": "Quels sont les symptômes du trouble lié au tabagisme ?\nComment se manifeste le sevrage tabagique ?\nLe tabagisme peut-il affecter l'humeur ?\nY a-t-il des symptômes physiques associés ?\nLes symptômes varient-ils selon les individus ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Trouble lié au tabagisme", "description": "Comment prévenir le trouble lié au tabagisme ?\nLes campagnes anti-tabac sont-elles efficaces ?\nQuel rôle jouent les écoles dans la prévention ?\nLes lois anti-tabac aident-elles à réduire la consommation ?\nLes programmes de cessation sont-ils accessibles ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Trouble lié au tabagisme", "description": "Quels traitements sont disponibles pour le tabagisme ?\nLes médicaments sont-ils efficaces contre le tabagisme ?\nQu'est-ce que la thérapie comportementale ?\nLes groupes de soutien sont-ils utiles ?\nCombien de temps dure un traitement pour le tabagisme ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Trouble lié au tabagisme", "description": "Quelles sont les complications du tabagisme ?\nLe tabagisme affecte-t-il la santé mentale ?\nLe tabagisme peut-il entraîner des problèmes de fertilité ?\nLes complications sont-elles réversibles ?\nLe tabagisme augmente-t-il le risque d'infections ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Trouble lié au tabagisme", "description": "Quels sont les principaux facteurs de risque du tabagisme ?\nL'âge influence-t-il le risque de tabagisme ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes publicités influencent-elles le tabagisme ?", "url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un trouble lié au tabagisme ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation des habitudes de consommation et des symptômes de dépendance." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la consommation régulière, le désir de réduire et les symptômes de sevrage." } }, { "@type": "Question", "name": "Qui peut poser le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Un professionnel de santé, comme un médecin ou un psychologue, peut poser le diagnostic." } }, { "@type": "Question", "name": "Y a-t-il des tests spécifiques pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de tests spécifiques, le diagnostic est basé sur l'entretien clinique." } }, { "@type": "Question", "name": "Le diagnostic peut-il être fait à distance ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des consultations en ligne peuvent permettre d'évaluer les habitudes de consommation." } }, { "@type": "Question", "name": "Quels sont les symptômes du trouble lié au tabagisme ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent le besoin urgent de fumer, l'irritabilité et les symptômes de sevrage." } }, { "@type": "Question", "name": "Comment se manifeste le sevrage tabagique ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le sevrage peut provoquer anxiété, dépression, troubles du sommeil et fringales." } }, { "@type": "Question", "name": "Le tabagisme peut-il affecter l'humeur ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut entraîner des fluctuations d'humeur et des troubles émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des symptômes physiques associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la toux, l'essoufflement et des douleurs thoraciques peuvent apparaître." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les individus ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la durée et de l'intensité de la consommation." } }, { "@type": "Question", "name": "Comment prévenir le trouble lié au tabagisme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par l'éducation, la sensibilisation et des politiques anti-tabac efficaces." } }, { "@type": "Question", "name": "Les campagnes anti-tabac sont-elles efficaces ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sensibilisent le public aux dangers du tabagisme et encouragent l'arrêt." } }, { "@type": "Question", "name": "Quel rôle jouent les écoles dans la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les écoles peuvent éduquer les jeunes sur les dangers du tabac et promouvoir des modes de vie sains." } }, { "@type": "Question", "name": "Les lois anti-tabac aident-elles à réduire la consommation ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des lois strictes sur la vente et la consommation de tabac réduisent son usage." } }, { "@type": "Question", "name": "Les programmes de cessation sont-ils accessibles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux programmes de cessation sont disponibles dans les centres de santé et en ligne." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour le tabagisme ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les substituts nicotiniques, les médicaments et la thérapie comportementale." } }, { "@type": "Question", "name": "Les médicaments sont-ils efficaces contre le tabagisme ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments comme la varénicline et le bupropion sont efficaces pour réduire le besoin de fumer." } }, { "@type": "Question", "name": "Qu'est-ce que la thérapie comportementale ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "C'est une approche qui aide à modifier les comportements liés à la consommation de tabac." } }, { "@type": "Question", "name": "Les groupes de soutien sont-ils utiles ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les groupes de soutien offrent un environnement d'encouragement et de partage d'expériences." } }, { "@type": "Question", "name": "Combien de temps dure un traitement pour le tabagisme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement varie, mais il est souvent recommandé de suivre un programme de plusieurs mois." } }, { "@type": "Question", "name": "Quelles sont les complications du tabagisme ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies cardiovasculaires, des cancers et des maladies respiratoires." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il la santé mentale ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est associé à des troubles de l'humeur, de l'anxiété et des problèmes de dépendance." } }, { "@type": "Question", "name": "Le tabagisme peut-il entraîner des problèmes de fertilité ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut réduire la fertilité chez les hommes et les femmes, affectant la reproduction." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec l'arrêt du tabac, mais pas toutes." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque d'infections ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il affaiblit le système immunitaire, augmentant le risque d'infections respiratoires." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque du tabagisme ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'exposition à la fumée, l'hérédité et des influences sociales." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de tabagisme ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes adultes sont plus susceptibles de commencer à fumer en raison de la pression sociale." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut inciter à fumer comme moyen de gestion des émotions et de l'anxiété." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, avoir des membres de la famille fumeurs augmente le risque de développer une dépendance." } }, { "@type": "Question", "name": "Les publicités influencent-elles le tabagisme ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les publicités peuvent normaliser le tabagisme et inciter les jeunes à commencer à fumer." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.

In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals.... This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ... It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high... As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o... PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u... More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ... Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...